Drugs / TRX-818
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02703298 | Mar 2016 → Jan 2018 | carcinoma | TaiRx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02507544 | Sep 2015 → Apr 2017 | carcinoma | TaiRx, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX-818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02507544 ↗ |
| Modality | Small molecule | “TRX-818 is a new small molecule chemical entity” NCT02507544 ↗ |
| Route | Oral | “TRX-818 Administered Orally to Patients With Advanced Cancer” NCT02507544 ↗ |